|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0032854,
umls-concept:C0033325,
umls-concept:C0035020,
umls-concept:C0138741,
umls-concept:C0178784,
umls-concept:C0185117,
umls-concept:C0376358,
umls-concept:C0750502,
umls-concept:C1282907,
umls-concept:C1366489,
umls-concept:C1413212,
umls-concept:C1417779,
umls-concept:C1561558,
umls-concept:C2698872,
umls-concept:C2911684
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2004-1-12
|
|
pubmed:abstractText |
The prognostic impact of tumor grading and staging is markedly reduced in organ confined or moderately differentiated prostate cancer, which underscores the importance of new prognostic markers. Evaluating public expression data of prostate cancer, we found an upregulation of the candidate gene CD24.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD24,
http://linkedlifedata.com/resource/pubmed/chemical/CD24 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Prostate-Specific Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0270-4137
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2003 Wiley-Liss, Inc.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
58
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
183-92
|
|
pubmed:dateRevised |
2005-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:14716744-Adenocarcinoma,
pubmed-meshheading:14716744-Aged,
pubmed-meshheading:14716744-Antigens, CD,
pubmed-meshheading:14716744-Antigens, CD24,
pubmed-meshheading:14716744-Disease Progression,
pubmed-meshheading:14716744-Disease-Free Survival,
pubmed-meshheading:14716744-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:14716744-Humans,
pubmed-meshheading:14716744-Immunohistochemistry,
pubmed-meshheading:14716744-Lymphatic Metastasis,
pubmed-meshheading:14716744-Male,
pubmed-meshheading:14716744-Membrane Glycoproteins,
pubmed-meshheading:14716744-Middle Aged,
pubmed-meshheading:14716744-Neoplasm Staging,
pubmed-meshheading:14716744-Prognosis,
pubmed-meshheading:14716744-Prostate-Specific Antigen,
pubmed-meshheading:14716744-Prostatic Neoplasms,
pubmed-meshheading:14716744-RNA, Messenger,
pubmed-meshheading:14716744-Regression Analysis,
pubmed-meshheading:14716744-Sensitivity and Specificity,
pubmed-meshheading:14716744-Tumor Markers, Biological,
pubmed-meshheading:14716744-Up-Regulation
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer.
|
|
pubmed:affiliation |
Institute of Pathology, Charité University Hospital, Berlin, Germany. glen.kristiansen@charite.de
|
|
pubmed:publicationType |
Journal Article
|
